Clinical Trial Update: Placebo-Controlled Trial of IFx-Hu2.0 Followed By Pembrolizumab In Checkpoint Inhibitor Naïve Participants With Advanced Or Metastatic Merkel Cell Carcinoma [Phase 2, Phase 3]

View source ↗

Summary

A Phase 2/Phase 3 trial evaluating IFx-Hu2.0 followed by pembrolizumab in checkpoint inhibitor–naïve patients with advanced or metastatic Merkel cell carcinoma;…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Merkel Cell Carcinoma

Drugs mentioned

• IFx-Hu2.0
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: TuHURA Biosciences, Inc. | Conditions: Advanced Or Metastatic Merkel Cell Carcinoma | Phase 2, Phase 3 | Status: RECRUITING